The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
![Spain Spain flag](https://www.greenhill.com/sites/default/files/spain.gif)
Farmalider Group
![Spain Spain flag](https://www.greenhill.com/sites/default/files/spain.gif)
Advising the shareholders of Grupo Farmalider, a B2B Spanish pharmaceutical company focused on contract manufacturing, innovation and development of products based on generics, on the sale of an undisclosed stake to local private equity MCH
![United Kingdom United Kingdom flag](https://www.greenhill.com/sites/default/files/uk.gif)
Kyowa Kirin International’s testosterone replacement therapy drug, Tostran®
![United Kingdom United Kingdom flag](https://www.greenhill.com/sites/default/files/uk.gif)
Advising Kyowa Kirin International, a subsidiary of Kyowa Kirin Co., Ltd, a Japanese global specialty pharma company, on the divestiture of its testosterone replacement therapy drug, Tostran®, to Advanz Pharma, a privately-held, specialty pharmaceutical company
![](https://www.greenhill.com/sites/default/files/greece-uk.png)
Clinigen Ltd’s Lamda Laboratories
![Germany Germany flag](https://www.greenhill.com/sites/default/files/germany.gif)
Advising Clinigen Ltd, a UK-based global pharmaceutical services company and portfolio company of Triton Partners, on the sale of Lamda Laboratories, a European contract development business, to Adragos Pharma, a Munich-based pharmaceutical CDMO
![](https://www.greenhill.com/sites/default/files/uk-japan.png)
Kyowa Kirin International’s established medicines business
![Germany Germany flag](https://www.greenhill.com/sites/default/files/germany.gif)
Advising Kyowa Kirin International, a subsidiary of Kyowa Kirin Co., Ltd, a Japanese global specialty pharma company, on a collaboration agreement with Grünenthal GmbH, a global, science-based, privately-owned pharmaceutical company
![United Kingdom United Kingdom flag](https://www.greenhill.com/sites/default/files/uk.gif)
Acacia Pharma Group plc
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advising Acacia, a UK-domiciled and Euronext-listed commercial stage biopharmaceutical company, on the sale to Eagle Pharmaceuticals, an integrated pharmaceutical company with R&D, manufacturing and commercial expertise
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Akorn Pharmaceuticals Portfolio of Branded Ophthalmic Products
![France France flag](https://www.greenhill.com/sites/default/files/france.gif)
Advised Akorn Pharmaceuticals, a specialty pharmaceuticals manufacturer and marketer, on the divestiture of its portfolio of branded ophthalmic products to Laboratoires Théa SAS
![Colombia Colombia flag](https://www.greenhill.com/sites/default/files/colombia-flag.png)
Procaps Group
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advised Procaps Group, a leading integrated international healthcare and pharmaceutical company, on its successful business combination with Union Acquisition Corp II (NASDAQ: LATN), a LatAm-focused special purpose acquisition company. Procaps Group now trades on the Nasdaq Global Market under the ticker symbol "PROC"
![Spain Spain flag](https://www.greenhill.com/sites/default/files/spain.gif)
Faes Farma, flagship product Bilastine
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advised Faes Farma in the signing of a long-term license agreement for its flagship product Bilastine with Hikma Specialty USA INC, a subsidiary of Hikma Pharmaceuticals PLC, for the United States of America
![Spain Spain flag](https://www.greenhill.com/sites/default/files/spain.gif)
Deltalab
![Thailand Thailand flag](https://www.greenhill.com/sites/default/files/Thailand_flag_60839.gif)
Advising Deltalab, a leading Spanish laboratory solutions provider with dedicated manufacturing capacity, on the sale of the company to SCG Packaging Public Company Limited, the largest integrated packaging and paper company in Southeast Asia
![](https://www.greenhill.com/sites/default/files/germany-france-spain.png)
Portfolio of 16 European Consumer Healthcare brands from Sanofi
![Germany Germany flag](https://www.greenhill.com/sites/default/files/germany.gif)
Advising Sanofi, a leading global player in the Consumer Healthcare market, on the divestiture of a portfolio of 16 European Consumer Healthcare brands to STADA, a German pharmaceutical and consumer healthcare company owned by Bain Capital and Cinven
![France France flag](https://www.greenhill.com/sites/default/files/france.gif)
Cosmetic applications endolysin
![Netherlands Netherlands flag](https://www.greenhill.com/sites/default/files/niederland.gif)
Advised Micreos, a fast-growing biotechnology company, on a long-term license agreement with L’Oréal for one of Micreos’ phage-based active ingredients, SA.100
![Japan Japan flag](https://www.greenhill.com/sites/default/files/japan.gif)
Centrifuge and processing equipment business of Koki Holdings Co., Ltd.
![Germany Germany flag](https://www.greenhill.com/sites/default/files/germany.gif)
Advised Eppendorf AG, a leading family-owned life science company, on the acquisition of the centrifuge and processing equipment business of KKR-owned Koki Holdings Co., Ltd., a manufacturer of power tools and centrifuge and processing equipment
![United Kingdom United Kingdom flag](https://www.greenhill.com/sites/default/files/uk.gif)
Global rights (excluding North America) to ThermaCare (United Kingdom)
![Italy Italy flag](https://www.greenhill.com/sites/default/files/italy.gif)
Advised GlaxoSmithKline plc (“GSK”), the UK listed international pharmaceutical and consumer healthcare company, on the divestiture of the global rights (excluding North America) for ThermaCare, including a dedicated manufacturing facility based in Albany, Georgia, USA, to Angelini Pharma
![Brazil Brazil flag](https://www.greenhill.com/sites/default/files/brazil.gif)
Cura Imagem e Diagnóstico Ltda.
![Brazil Brazil flag](https://www.greenhill.com/sites/default/files/brazil.gif)
Advised Cura, a leading independent provider of diagnostic imaging (MRI, CT, etc.) and other clinical analysis services on the sale of 70% of its stake to the PE fund Vinci Partners
![Brazil Brazil flag](https://www.greenhill.com/sites/default/files/brazil.gif)
Cura Imagem e Diagnóstico Ltda.
![Brazil Brazil flag](https://www.greenhill.com/sites/default/files/brazil.gif)
Advising Cura, a leading independent provider of diagnostic imaging (MRI, CT, etc.) and other clinical analysis services on the sale of 70% of its stake to the PE fund Vinci Partners
![Switzerland Switzerland flag](https://www.greenhill.com/sites/default/files/switzerland.gif)
Novartis AG’s 36.5% stake in Consumer Health Joint Venture
![United Kingdom United Kingdom flag](https://www.greenhill.com/sites/default/files/uk.gif)
Advised and acted as sponsor to GlaxoSmithKline plc, the UK’s leading pharmaceutical company, on the buyout of Novartis’ 36.5% stake in their Consumer Health Joint Venture
![Germany Germany flag](https://www.greenhill.com/sites/default/files/germany.gif)
MorphoSys AG
![China China flag](https://www.greenhill.com/sites/default/files/china.gif)
Advised MorphoSys AG, a German biopharmaceutical company, on a regional licensing agreement covering Greater China and comprising its investigational anti-CD38 antibody MOR202 targeting multiple myeloma, with I-Mab
![Brazil Brazil flag](https://www.greenhill.com/sites/default/files/brazil.gif)
Radiogroup Participações S.A.
![Brazil Brazil flag](https://www.greenhill.com/sites/default/files/brazil.gif)
Advised Radiogroup, a regional leader in cancer treatment through radiotherapy, on its sale of a majority stake to Grupo Oncoclínicas
![Israel Israel flag](https://www.greenhill.com/sites/default/files/israel.gif)
Portfolio of generic marketed products in France from Teva Pharmaceutical Industries Ltd.
![France France flag](https://www.greenhill.com/sites/default/files/france.gif)
Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on the divestment of a portfolio of generic marketed products in France to Arrow Generiques SAS (a subsidiary of Aurobindo Pharma Limited).
![Germany Germany flag](https://www.greenhill.com/sites/default/files/germany.gif)
Boehringer Ingelheim
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advised Boehringer Ingelheim, the world's largest privately held pharmaceutical company, on a global collaboration with AbbVie regarding an investigational monoclonal IL-23 antibody targeting autoimmune diseases. Within the scope of the agreement, AbbVie also acquired an option for the development and commercialisation of BI’s anti-CD-40 antibody.
![United Kingdom United Kingdom flag](https://www.greenhill.com/sites/default/files/uk.gif)
Allied Healthcare
![Germany Germany flag](https://www.greenhill.com/sites/default/files/germany.gif)
Advised Saga plc on the disposal of Allied Healthcare, the leading local authority-funded domiciliary care business in the UK, to AURELIUS Investments
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
MannKind Corporation
![France France flag](https://www.greenhill.com/sites/default/files/france.gif)
Advised MannKind, a biopharmaceutical company focused on the development of therapeutic products for patients with diabetes, on a collaboration with Sanofi, comprising licensing, supply and loan facility agreements with respect to licensing the Company’s lead product AFREZZA. MannKind will receive up to $925 million in upfront and milestone payments plus 35% of future profits.
![USA/Germany U.S.A., Germany flags](https://www.greenhill.com/sites/default/files/usa_germany.gif)
Siemens Health Services
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advised Cerner Corporation, a leader in healthcare information services, on the acquisition of the assets of Siemens Aktiengesellschaft’s healthcare information technology business unit, Siemens Health Services, for $1.3 billion in cash.
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Forest Laboratories Inc.
![Ireland Ireland flag](https://www.greenhill.com/sites/default/files/ireland.gif)
Advised Actavis plc, a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products on its acquisition of Forest Laboratories Inc.
![Ireland Ireland flag](https://www.greenhill.com/sites/default/files/ireland.gif)
Warner Chilcott, plc
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advised Actavis, Inc., a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, branded and biosimilar products on its acquisition of Warner Chilcott plc